Select Page

Women in Ophthalmology Podcasts

Season 2 has launched!

10 minutes of science is a podcast series from Women in Ophthalmology. Each edition features an expert in their field discussing an article of their choosing. These articles have been selected due to their impact on the real-world practice of ophthalmology. The series is aimed at the general comprehensive ophthalmologists and includes topics across a range of subspecialities.

With the hugely successful launch of the first season in November 2021, we are proud to present the second series the podcast! A new episode was released every week over nine weeks. Hosted by Women in Ophthalmology Deputy Chair, Dr Robyn Troutbeck, we welcome you to listen to 10 minutes of science.

This series was made possible with support from Johnson & Johnson Vision.

Season 2 – About the Podcasts

1. Can weight loss cure eye disease? Effectiveness of Bariatric Sugery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension

Can weight loss cure eye disease? In the case of Idiopathic Intracranial Hypertension (IIH), yes! A/Prof Clare Fraser talks us through the much-awaited follow-up article examining the Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of IIH. The main take-away is not pizza – listen in to find out what is it! View article.

2. Mucking out the stables. The Ruptured Globe, Sympathetic Ophthalmia, and the 14-Day Rule

Dr Freny Kalapesi examines the basis of the 14-day rule in treating ruptured globes to prevent sympathetic ophthalmia. A key takeaway is understanding the importance of whole-of-person care when considering treatment options. View the article.

3. Considering it all Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3- year follow- up study

Dr Caroline Catt investigates myopia progression and axial elongation in children. Limitations on data impact treatment choices – what should be considered for DIMs lenses? Age, ethnicity, cost, access? Caroline considers it all, providing practical advice for anyone seeing children. View article.

4. Beyond the surface Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial

A modern landmark glaucoma trial and first-of-its-kind that provides surprising and useful outcomes for current practice and research. Can the visual field be preserved with an intraocular-pressure-lowering drug in patients with open-angle glaucoma? Dr Jennifer Fan Gaskin explores Latanoprost for open-angle glaucoma. View article.

5. Rebounds are not limited to basketball. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout.

Rebounds are not limited to basketball. Dr Sarah Hull examines the rebound effect in the Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study. What are the outcomes of continued atropine treatment, and what is the ideal concentration?

6. Talking “pulleyes”… and when they no longer hold tension

When a trans-pacific collaboration results in need-to-know outcomes for the general ophthalmologist. The differences in patterns of sagging eye syndrome lead to different treatment paths. Dr Sonia Moorthy unpacks diagnosis, simple and effective management strategies and ways to reduce unnecessary investigations. View article.

7. For Fuchs’s sake, taking out the sting. Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs’ Endothelial Dystrophy

Professor Stephanie Watson talks taking the sting out of Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs’ Endothelial Dystrophy. Do the clinical outcomes support their use, and how robust was this Double-Masked, Randomized Controlled Trial?

8. Superiority complex? It is complex

Associate Professor Susan Carden examines the RAINBOW study, which compared treatment of ROP with ranibizumab versus laser therapy. Noting the extension trial may uncover more, there might be a superior treatment method. Listen in to find out more. View article.

9. Impressed with a 50% success rate?

Witnessing blinding acute angle attacks motivated Dr Judy Ku’s passion for primary angle closure disease. She explores how a 50% success rate sounds impressive, but its real-world outcomes are less, especially when factoring in the economic costs of large population screening and proactive treatment. So, while laser peripheral iridotomy is effective in reducing the risk progression to primary angle closure and acute angle closure attacks – what are the caveats? Listen in to find out. View Article.

Season 1 – About the Podcasts

1. Rituximab for Non-infectious Uveitis and Scleritis

Is rituximab a wonder-drug? Dr Diana Conrad, Director of the Uveitis Service at the Royal Women’s and Children’s Hospital (the only speciality uveitis service in Queensland) explores Rituximab for non-infectious Uveitis and Scleritis. Dr Conrad notes an impressive response rate to rituximab for patients where first and second line treatments have failed. Given the success of rituximab, and the biosimilars entering the market, Diana includes some important messages for ophthalmologists using the drug.

2. Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic

Dr Cheryl Au, current medical retinal fellow at Westmead Hospital, explores Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy. She was prompted to review the article due to frequent presentation of patients presenting with vitreous haemorrhage from PDR, and the desire to identify evidence-based guidelines for best visual outcomes once intervention is decided. Dr Au explores the robustness of the study, as well as explaining the outcomes and how these can be used to guide clinical practice.

3. Selective Laser Trabeculoplasty: A Review

Selective laser trabeculoplasty (SLT) has become an essential part of glaucoma management. Dr Alina Zeldovich explores Selective laser trabeculoplasty: A review published in RANZCO’s own Clinical and Experimental Ophthalmology. Dr Zeldovich is a cataract surgeon who has been using SLT more frequently on her glaucoma patients. She discusses the significance of this review to her own clinical practice. Hear more about the article, including the various subgroups of glaucoma where SLT is being used and what outcomes it is achieving.

4. Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for more than 4 Months (VICI)

The VICI trial is highly topical. Dr Narme Deva, Consultant Ophthalmologist & Honorary Senior Lecturer at the University of Auckland, explores the Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. She explains the results are unequivocal and based on a robust trial of 114 patients. Eplerenone does not improve BCVA in people with chronic CSCR after 12 months of treatment. As ever, Dr Deva reminds listeners that evidence-based medicine includes using reliable data to make decisions, even when patients and ophthalmologists are faced with limited treatment options to prevent vision loss.

5. Clinical Results of Topgraphy-based Customized Ablations in Highly Aberrated Eyes and Karatoconus/ectasia with Cross-linking

On the laser’s edge – breaking taboos! Dr Aanchal Gupta is the Director of Training for the South Australian Training network and a Senior Clinical lecturer at the University of Adelaide. She reviews Clinical results of topography-based customized ablations in highly aberrated eyes and keratoconus/ectasia with cross-linking, the article as written by her fellowship mentors that started her interest in refractive surgery. The results demonstrate how laser platforms can go beyond routine vision correction. Irregular astigmatism, keratoconus patients and those with decentred ablations can be successfully treated with laser. This allows patients to avoid rigid contact lenses, transplants or glasses with suboptimal vision. Do the results last? What are the long-term outcomes? What can go wrong? Dr Gupta explores…

6. Accuracy of Intraocular Lens Power Formulas Modified for Patients with Keratoconus

Which IOL formula should we use prior to cataract surgery in patients with keratoconus? Are the newer formulae with keratoconus modifications more accurate than the regular formulae that we are used to using? What should be our refractive target for these cases and how does it vary according to severity of the cone? Can we aim for spectacle independence? Dr Jacqueline Beltz, Cornea, Cataract and Refractive Surgeon from Melbourne explains why refractive outcomes are tricky to predict in eyes with keratoconus. She explores Accuracy of Intraocular Lens Power Formulas Modified for Patients with Keratoconus by Jack Kane and colleagues that seeks to answer these very questions. Tune in to find out!

7. Laser-assisted in Situ Keratomileusis Long Term Outcomes in Late Adolescence

Dr Tanya Trinh – Coming

8. The Pneumatic Retinopexy vs. Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT)

Dr Mali Okada is a consultant at the RVEEH and senior researcher at CERA. In this podcast, she discusses the various management options of retinal detachment. Pneumatic retinopexy is routinely used as the first line treatment in many parts of the world for superior retinal detachments, but this is not always the case in Australia and New Zealand where vitrectomy is preferred. The PIVOT study unpacks the issues, looking at repeat visits, surgical and visual outcomes, requirement for follow-up cataract surgery and more. The study has some limitations but is thought-provoking. It is essential to define the markers of success to support surgeons in determining the best course of action for their patients.

9. Periocular Triamcinolone vs Intravitreal Triamcinolone vs Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs Intravitreal Corticisteroids for Uveitic Macular Edema (POINT) Trial

Dr Priya Samalia is a medical retina and uveitis fellow working at the Royal Victorian Eye and Ear Hospital. She examines the POINT trial on effectiveness of Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the treatment of non-infectious uveitic macular oedema. Dr Samalia explains that the trail is important because macular oedema is a common cause of vision loss for patient with uveitis and management can be challenging. The paper is a head-to-head comparison and broadly represents a real-world patient mix. While it finds intravitreal treatments are superior, Priya notes there are valid reasons to perform periocular injections.

10. Associations Between Anterior Segment Parameters and Rotational Stability of a Plate-haptic Toric Intraocular Lens

At face value – does the data always support the conclusion? Dr Madeleine Adams, a cataract surgeon and comprehensive ophthalmologist with a PhD from the University of Melbourne for her research into age-related macular degeneration, offers a cautionary message about always critically scrutinising data presented in papers and coming to your own conclusion on whether the data supports the conclusions. In the case of Associations between anterior segment parameters and the rotational stability of a plate-haptic toric intraocular lens, with a closer look, the data aren’t so convincing.

11. Factors Affecting Corneal Incision Position During Femtosecond Laser-assisted Cataract Surgery

Dr Kerrie Meades was the first female ophthalmologist to perform laser vision correct in Australia. In this podcast, Dr Meades discusses the article Factors affecting corneal incision position during femtosecond laser-assisted cataract surgery. Kerrie was prompted to explore this topic due to a lack of precision from laser for the second incision. Tilt and displacement can affect the translation of the program of the laser and the actual incision. As such, OCT guidance is needed for the secondary incision, as you do for the primary incision. Kerrie provides an insight into how patient behaviour and anatomy can affect docking, and therefore incisions.

Last updated: November 24, 2022

Get in Touch

Do you have any queries or comments about our website, our products or any  of our services?
RANZCO acknowledges our First Australians, the Traditional Custodians of the land
on which we live and work, and pays respect to Elders past, present and emerging.
Gadigal people of the Eora Nation are the traditional custodians of the land
where the RANZCO head office is located.
In recognition that we are a bi-national College, we also
acknowledge the Rangatiratanga of Māori as Tangata Whenua
and Treaty of Waitangi partners in Aotearoa New Zealand.